HUMA$0.411212.47%-0.0586
After Hours: 0.43+0.02 +4.57%
Humacyte Inc (HUMA)
Date: 2026-10-30 16:00O: 0.4600H: 0.4600L: 0.4000C: 0.4112Vol: 5.063M
Humacyte Inc stock is traded at $0.4112, with a volume of 5,063,325. It is down -12.47% in the last 24 hours and down -20.57% over the past month. Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Previous Close:
$0.4698
Open:
$0.46
24h Volume:
5,063,325
Relative Volume:
1.34
Market Cap:
$114.23M
Revenue:
$2.02M
Net Income/Loss:
-$97.59M
P/E Ratio:
-
EPS:
-$0.5747
Net Cash Flow:
-$102.38M
1W Performance:
-5.56%
1M Performance:
-20.57%
6M Performance:
-51.15%
1Y Performance:
-74.62%
1-Day Range:
$0.4$0.46
1-Week Range:
$0.391$0.51
52-Week Range:
$0.337$1.70
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte IncSector
HealthcareIndustry
BiotechnologyPhone
919-313-9633Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, USACompare HUMA vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA Humacyte Inc | $0.4112 | $114.23M | $2.02M | -$97.59M | -$102.38M | -$0.5747 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Humacyte Inc Stock (HUMA) Insider Trading
- Jones Keith AnthonyAug 20 '26Director
- Transaction
- Buy
- Cost
- $0.69
- #Shares
- 10,000
- Value ($)
- 6,930
- #Shares Total
- 40,000
- Jones Keith AnthonyAug 17 '26Director
- Transaction
- Buy
- Cost
- $0.59
- #Shares
- 30,000
- Value ($)
- 17,820
- #Shares Total
- 30,000
- Sebelius KathleenMay 19 '26Director
- Transaction
- Buy
- Cost
- $0.88
- #Shares
- 56,818
- Value ($)
- 50,000
- #Shares Total
- 148,025
- Constantino Michael T.May 18 '26Director
- Transaction
- Buy
- Cost
- $0.89
- #Shares
- 11,000
- Value ($)
- 9,840
- #Shares Total
- 43,950
- Sander Dale A.May 18 '26CFO and Chief Corp. Dev. Off
- Transaction
- Sale
- Cost
- $0.9
- #Shares
- 45,887
- Value ($)
- 41,147
- #Shares Total
- 267,213
- Parikh Shamik JMay 18 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $0.9
- #Shares
- 45,887
- Value ($)
- 41,147
- #Shares Total
- 272,713
- Sander Dale A.May 18 '26Officer
- Transaction
- Proposed Sale
- Cost
- $0.9
- #Shares
- 45,887
- Value ($)
- 41,147
- #Shares Total
- 0
- Parikh Shamik JMay 18 '26Officer
- Transaction
- Proposed Sale
- Cost
- $0.9
- #Shares
- 45,887
- Value ($)
- 41,147
- #Shares Total
- 0
